Jennifer L. Goralski, MD

Assistant Professor
The University of North Carolina at Chapel Hill

Poster(s):

• (256) Tobramycin Pharmacokinetic Differences in Patients After Initiation of Highly Effective Modulator Therapy
  Thursday, November 3, 2022

  12:00 PM – 12:40 PM ET

• (326) Prevalence of substance use in adult cystic fibrosis patients
  Thursday, November 3, 2022

  12:00 PM – 12:40 PM ET

• (334) Who Are We Excluding? An RCT for Adults With Cystic Fibrosis That Includes Those With Moderate to Severe Symptoms of Depression and Anxiety
  Thursday, November 3, 2022

  12:00 PM – 12:40 PM ET

• (453) VDP comparison between spiral with post-acquisition denoising and cartesian acquisition for 19F lung MRI
  Thursday, November 3, 2022

  12:45 PM – 1:25 PM ET

• (464) Impact of Elexacaftor/Tezacaftor/Ivacaftor on the Sinonasal Microbiome
  Thursday, November 3, 2022

  12:00 PM – 12:40 PM ET

• (574) Determining the Minimal Clinically Important Difference for the 22-Question SinoNasal Outcome Test (SNOT-22) in People with Cystic Fibrosis
  Thursday, November 3, 2022

  12:00 PM – 12:40 PM ET

• (693) A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 2 Through 5 Years of Age with Cystic Fibrosis and at Least One F508del Allele
  Thursday, November 3, 2022

  12:45 PM – 1:25 PM ET